Titre : Benzodiazépines

Benzodiazépines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hypnotics and Sedatives

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzodiazépines ?

Le diagnostic repose sur l'évaluation des symptômes et l'historique d'utilisation des médicaments.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzodiazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont utilisés pour le diagnostic ?

Les critères DSM-5 incluent l'usage excessif et les symptômes de sevrage.
Troubles liés à l'usage de substances Benzodiazépines
#4

Comment évaluer l'efficacité d'un traitement par benzodiazépines ?

L'efficacité est évaluée par la réduction des symptômes d'anxiété ou d'insomnie.
Évaluation clinique Benzodiazépines
#5

Quels signes indiquent une surdose de benzodiazépines ?

Les signes incluent confusion, somnolence excessive et difficultés respiratoires.
Syndrome de sevrage Benzodiazépines

Symptômes 5

#1

Quels sont les effets secondaires courants des benzodiazépines ?

Les effets secondaires incluent somnolence, vertiges et troubles de la mémoire.
Effets indésirables Benzodiazépines
#2

Comment reconnaître une réaction allergique aux benzodiazépines ?

Les réactions allergiques peuvent se manifester par éruptions cutanées et démangeaisons.
Réactions allergiques Benzodiazépines
#3

Quels symptômes indiquent un sevrage des benzodiazépines ?

Les symptômes de sevrage incluent anxiété, insomnie et tremblements.
Syndrome de sevrage Benzodiazépines
#4

Les benzodiazépines provoquent-elles des troubles cognitifs ?

Oui, elles peuvent entraîner des troubles de la mémoire et de la concentration.
Troubles cognitifs Benzodiazépines
#5

Quels symptômes peuvent nécessiter une consultation médicale urgente ?

Des symptômes comme confusion sévère ou difficultés respiratoires nécessitent une urgence.
Urgences médicales Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzodiazépines ?

La prévention inclut une prescription prudente et une éducation sur les risques.
Prévention de la dépendance Benzodiazépines
#2

Quels conseils donner aux patients sur l'utilisation des benzodiazépines ?

Les patients doivent être informés des risques et de l'importance de suivre les prescriptions.
Éducation des patients Benzodiazépines
#3

Comment surveiller l'utilisation des benzodiazépines ?

Les médecins doivent effectuer des suivis réguliers pour évaluer l'usage et les effets.
Suivi médical Benzodiazépines
#4

Quelles stratégies non médicamenteuses peuvent aider ?

Des techniques comme la méditation et l'exercice physique peuvent réduire l'anxiété.
Thérapies alternatives Benzodiazépines
#5

Comment sensibiliser sur les risques des benzodiazépines ?

Des campagnes d'information et des ateliers peuvent sensibiliser le public aux risques.
Sensibilisation Benzodiazépines

Traitements 5

#1

Comment traiter une dépendance aux benzodiazépines ?

Le traitement inclut une désintoxication supervisée et une thérapie comportementale.
Dépendance aux médicaments Benzodiazépines
#2

Quelles alternatives existent aux benzodiazépines pour l'anxiété ?

Les alternatives incluent les antidépresseurs et les thérapies cognitivo-comportementales.
Antidépresseurs Benzodiazépines
#3

Comment réduire progressivement l'utilisation des benzodiazépines ?

La réduction doit être progressive, sous supervision médicale pour éviter le sevrage.
Sevrage Benzodiazépines
#4

Quels médicaments peuvent aider à gérer le sevrage ?

Des médicaments comme le diazépam peuvent être utilisés pour atténuer les symptômes de sevrage.
Sevrage Benzodiazépines
#5

Quelle est la durée recommandée pour l'utilisation des benzodiazépines ?

L'utilisation est généralement recommandée pour une courte durée, souvent moins de 4 semaines.
Durée du traitement Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec l'usage prolongé ?

L'usage prolongé peut entraîner des troubles cognitifs et une dépendance sévère.
Complications Benzodiazépines
#2

Comment les benzodiazépines affectent-elles la santé mentale ?

Elles peuvent aggraver des troubles mentaux comme la dépression et l'anxiété.
Santé mentale Benzodiazépines
#3

Quels risques sont associés à l'association avec d'autres médicaments ?

L'association avec des opioïdes ou l'alcool augmente le risque de dépression respiratoire.
Interactions médicamenteuses Benzodiazépines
#4

Les benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?

Oui, elles augmentent le risque de chutes et de fractures chez les personnes âgées.
Chutes Benzodiazépines
#5

Quels effets à long terme sur la mémoire sont observés ?

L'usage prolongé peut entraîner des troubles de la mémoire et des difficultés d'apprentissage.
Troubles de la mémoire Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance ?

Les antécédents de troubles mentaux et l'usage prolongé augmentent le risque de dépendance.
Facteurs de risque Benzodiazépines
#2

Comment l'âge influence-t-il l'usage des benzodiazépines ?

Les personnes âgées sont plus susceptibles de subir des effets secondaires et des complications.
Âge Benzodiazépines
#3

Quel rôle joue l'environnement social dans l'usage ?

Un environnement stressant ou un manque de soutien social peut augmenter l'usage des benzodiazépines.
Environnement social Benzodiazépines
#4

Les antécédents familiaux influencent-ils l'usage ?

Oui, des antécédents familiaux de dépendance peuvent augmenter le risque d'usage problématique.
Antécédents familiaux Benzodiazépines
#5

Comment les troubles de santé mentale affectent-ils l'usage ?

Les personnes avec des troubles de santé mentale sont plus susceptibles d'utiliser des benzodiazépines.
Troubles mentaux Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines : Questions médicales les plus fréquentes", "headline": "Benzodiazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzodiazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-04", "dateModified": "2025-04-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzodiazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Benzazépines", "url": "https://questionsmedicales.fr/mesh/D001552", "about": { "@type": "MedicalCondition", "name": "Benzazépines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Babette Bais", "url": "https://questionsmedicales.fr/author/Babette%20Bais", "affiliation": { "@type": "Organization", "name": "Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands." } }, { "@type": "Person", "name": "Steven Wright", "url": "https://questionsmedicales.fr/author/Steven%20Wright", "affiliation": { "@type": "Organization", "name": "Former medical director of the Alliance for Benzodiazepine Best Practices, Portland, OR, a nonprofit resource for physicians and patients." } }, { "@type": "Person", "name": "Christine Champion", "url": "https://questionsmedicales.fr/author/Christine%20Champion", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France." } }, { "@type": "Person", "name": "Teddy Novais", "url": "https://questionsmedicales.fr/author/Teddy%20Novais", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Service pharmaceutique, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Inserm U1290, Lyon, France." } }, { "@type": "Person", "name": "Jean-Michel Dorey", "url": "https://questionsmedicales.fr/author/Jean-Michel%20Dorey", "affiliation": { "@type": "Organization", "name": "Université Lyon 1, Lyon, France, Centre Hospitalier Le Vinatier, Bron, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Provider knowledge, beliefs, and self-efficacy to deprescribe opioids and sedative-hypnotics.", "datePublished": "2022-12-22", "url": "https://questionsmedicales.fr/article/36546768", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jgs.18202" } }, { "@type": "ScholarlyArticle", "name": "Trends, correlates, and disease patterns of sedative-hypnotic use among elderly persons in Taiwan.", "datePublished": "2022-05-04", "url": "https://questionsmedicales.fr/article/35508990", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12888-022-03964-6" } }, { "@type": "ScholarlyArticle", "name": "The epidemiology of new persistent hypnotic/sedative use after surgical procedures: a retrospective cohort study.", "datePublished": "2023-05-15", "url": "https://questionsmedicales.fr/article/37188390", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/anae.16041" } }, { "@type": "ScholarlyArticle", "name": "Use of hypnotic-sedative medication and risk of falls and fractures in adults: A self-controlled case series study.", "datePublished": "2023-09-04", "url": "https://questionsmedicales.fr/article/37665682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/acps.13610" } }, { "@type": "ScholarlyArticle", "name": "Characterising incident opioid use among incident users of prescription sedative hypnotics: A national cohort study.", "datePublished": "2024-05-30", "url": "https://questionsmedicales.fr/article/38816043", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2023-082339" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" }, { "@type": "ListItem", "position": 6, "name": "Benzodiazépines", "item": "https://questionsmedicales.fr/mesh/D001569" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzodiazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzodiazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzodiazépines", "description": "Comment diagnostiquer une dépendance aux benzodiazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzodiazépines ?\nQuels critères DSM sont utilisés pour le diagnostic ?\nComment évaluer l'efficacité d'un traitement par benzodiazépines ?\nQuels signes indiquent une surdose de benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzodiazépines", "description": "Quels sont les effets secondaires courants des benzodiazépines ?\nComment reconnaître une réaction allergique aux benzodiazépines ?\nQuels symptômes indiquent un sevrage des benzodiazépines ?\nLes benzodiazépines provoquent-elles des troubles cognitifs ?\nQuels symptômes peuvent nécessiter une consultation médicale urgente ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzodiazépines", "description": "Comment prévenir la dépendance aux benzodiazépines ?\nQuels conseils donner aux patients sur l'utilisation des benzodiazépines ?\nComment surveiller l'utilisation des benzodiazépines ?\nQuelles stratégies non médicamenteuses peuvent aider ?\nComment sensibiliser sur les risques des benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzodiazépines", "description": "Comment traiter une dépendance aux benzodiazépines ?\nQuelles alternatives existent aux benzodiazépines pour l'anxiété ?\nComment réduire progressivement l'utilisation des benzodiazépines ?\nQuels médicaments peuvent aider à gérer le sevrage ?\nQuelle est la durée recommandée pour l'utilisation des benzodiazépines ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzodiazépines", "description": "Quelles complications peuvent survenir avec l'usage prolongé ?\nComment les benzodiazépines affectent-elles la santé mentale ?\nQuels risques sont associés à l'association avec d'autres médicaments ?\nLes benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?\nQuels effets à long terme sur la mémoire sont observés ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzodiazépines", "description": "Quels facteurs augmentent le risque de dépendance ?\nComment l'âge influence-t-il l'usage des benzodiazépines ?\nQuel rôle joue l'environnement social dans l'usage ?\nLes antécédents familiaux influencent-ils l'usage ?\nComment les troubles de santé mentale affectent-ils l'usage ?", "url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Hypnotics+and+Sedatives#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzodiazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation des symptômes et l'historique d'utilisation des médicaments." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzodiazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont utilisés pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 incluent l'usage excessif et les symptômes de sevrage." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité d'un traitement par benzodiazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des symptômes d'anxiété ou d'insomnie." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzodiazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive et difficultés respiratoires." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants des benzodiazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent somnolence, vertiges et troubles de la mémoire." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique aux benzodiazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les réactions allergiques peuvent se manifester par éruptions cutanées et démangeaisons." } }, { "@type": "Question", "name": "Quels symptômes indiquent un sevrage des benzodiazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes de sevrage incluent anxiété, insomnie et tremblements." } }, { "@type": "Question", "name": "Les benzodiazépines provoquent-elles des troubles cognitifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire et de la concentration." } }, { "@type": "Question", "name": "Quels symptômes peuvent nécessiter une consultation médicale urgente ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme confusion sévère ou difficultés respiratoires nécessitent une urgence." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzodiazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut une prescription prudente et une éducation sur les risques." } }, { "@type": "Question", "name": "Quels conseils donner aux patients sur l'utilisation des benzodiazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les patients doivent être informés des risques et de l'importance de suivre les prescriptions." } }, { "@type": "Question", "name": "Comment surveiller l'utilisation des benzodiazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les médecins doivent effectuer des suivis réguliers pour évaluer l'usage et les effets." } }, { "@type": "Question", "name": "Quelles stratégies non médicamenteuses peuvent aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme la méditation et l'exercice physique peuvent réduire l'anxiété." } }, { "@type": "Question", "name": "Comment sensibiliser sur les risques des benzodiazépines ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des ateliers peuvent sensibiliser le public aux risques." } }, { "@type": "Question", "name": "Comment traiter une dépendance aux benzodiazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut une désintoxication supervisée et une thérapie comportementale." } }, { "@type": "Question", "name": "Quelles alternatives existent aux benzodiazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les alternatives incluent les antidépresseurs et les thérapies cognitivo-comportementales." } }, { "@type": "Question", "name": "Comment réduire progressivement l'utilisation des benzodiazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La réduction doit être progressive, sous supervision médicale pour éviter le sevrage." } }, { "@type": "Question", "name": "Quels médicaments peuvent aider à gérer le sevrage ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le diazépam peuvent être utilisés pour atténuer les symptômes de sevrage." } }, { "@type": "Question", "name": "Quelle est la durée recommandée pour l'utilisation des benzodiazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation est généralement recommandée pour une courte durée, souvent moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'usage prolongé ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé peut entraîner des troubles cognitifs et une dépendance sévère." } }, { "@type": "Question", "name": "Comment les benzodiazépines affectent-elles la santé mentale ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent aggraver des troubles mentaux comme la dépression et l'anxiété." } }, { "@type": "Question", "name": "Quels risques sont associés à l'association avec d'autres médicaments ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'association avec des opioïdes ou l'alcool augmente le risque de dépression respiratoire." } }, { "@type": "Question", "name": "Les benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes et de fractures chez les personnes âgées." } }, { "@type": "Question", "name": "Quels effets à long terme sur la mémoire sont observés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé peut entraîner des troubles de la mémoire et des difficultés d'apprentissage." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles mentaux et l'usage prolongé augmentent le risque de dépendance." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il l'usage des benzodiazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées sont plus susceptibles de subir des effets secondaires et des complications." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement social dans l'usage ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement stressant ou un manque de soutien social peut augmenter l'usage des benzodiazépines." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils l'usage ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de dépendance peuvent augmenter le risque d'usage problématique." } }, { "@type": "Question", "name": "Comment les troubles de santé mentale affectent-ils l'usage ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes avec des troubles de santé mentale sont plus susceptibles d'utiliser des benzodiazépines." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 29/04/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

24 au total
└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Babette Bais

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands.

Steven Wright

2 publications dans cette catégorie

Affiliations :
  • Former medical director of the Alliance for Benzodiazepine Best Practices, Portland, OR, a nonprofit resource for physicians and patients.

Christine Champion

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France.
Publications dans "Benzodiazépines" :

Teddy Novais

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Service pharmaceutique, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Inserm U1290, Lyon, France.
Publications dans "Benzodiazépines" :

Jean-Michel Dorey

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Centre Hospitalier Le Vinatier, Bron, France.
Publications dans "Benzodiazépines" :

Pierre Krolak-Salmon

2 publications dans cette catégorie

Affiliations :
  • Université Lyon 1, Lyon, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neurosciences de Lyon, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France.
Publications dans "Benzodiazépines" :

Alexis Lepetit

2 publications dans cette catégorie

Affiliations :
  • Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, CNRS UMR 5229, Institut des Sciences Cognitives Marc-Jeannerod, Team "Neuroplasticity in Parkinson's disease".
Publications dans "Benzodiazépines" :

Richard Balon

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne State University, Detroit, MI, USA. rbalon@wayne.edu.
Publications dans "Benzodiazépines" :

Vladan Starcevic

2 publications dans cette catégorie

Affiliations :
  • Discipline of Psychiatry, Nepean Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Publications dans "Benzodiazépines" :

Md Yeunus Mian

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Dishary Sharmin

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Prithu Mondal

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Jawad Bin Belayet

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

M Mahmun Hossain

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Paul McCusker

2 publications dans cette catégorie

Affiliations :
  • Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Kaetlyn T Ryan

2 publications dans cette catégorie

Affiliations :
  • Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Alexander Y Fedorov

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Heather A Green

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Spencer S Ericksen

2 publications dans cette catégorie

Affiliations :
  • UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Mostafa Zamanian

2 publications dans cette catégorie

Affiliations :
  • Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Publications dans "Benzodiazépines" :

Sources (1775 au total)

Provider knowledge, beliefs, and self-efficacy to deprescribe opioids and sedative-hypnotics.

While many studies have assessed and measured patient attitudes toward deprescribing, less quantitative research has addressed the provider perspective. We thus sought to describe provider knowledge, ... An electronic anonymous survey was distributed to primary care providers at Kaiser Permanente Washington. Two reminder emails were sent. The survey included 10 questions on general deprescribing, and ... Of 370 eligible primary care providers, 95 (26%) completed the survey. For general deprescribing questions, a majority believed that lack of patient willingness, withdrawal symptoms and fear of sympto... Results suggest that raising provider awareness of patient willingness to deprescribe, addressing knowledge gaps, and increasing self-efficacy for deprescribing are important targets for improving dep...

Trends, correlates, and disease patterns of sedative-hypnotic use among elderly persons in Taiwan.

The population-based National Health Insurance database was adopted to investigate the prevalence, correlates, and disease patterns of sedative-hypnotic use in elderly persons in Taiwan.... The National Health Research Institutes provided a database of 1,000,000 random subjects in the National Health Insurance program. We adopted this sample of subjects who were older than 65 years from ... The 1-year prevalence of sedative-hypnotic use in elderly individuals increased from 1.7% in 1997 to 5.5% in 2005. The 1-year prevalence rates of benzodiazepine (BZD) and non-BZD hypnotics were 3.2 an... The prevalence rates of both BZD and non-BZD sedative-hypnotic use increased from 1997 to 2005 in the elderly. The risk factors for sedative-hypnotic use were aging, male sex, lower insurance amount, ...

Use of hypnotic-sedative medication and risk of falls and fractures in adults: A self-controlled case series study.

To evaluate the risk of falls and fractures in users of benzodiazepines, Z-drugs, or melatonin.... We followed 699,335 adults with a purchase of benzodiazepines, Z-drugs, or melatonin in the Danish National Prescription Registry between 2003 and 2016 for falls and fractures in the Danish National P... In total 62,105 and 36,808 adults, respectively, experienced a fall or fracture. For older adults, the risk of falls was highest during the 3-month pre-treatment period (IRR... Although falls and fractures occur more often in persons using sedative-hypnotic medication, the higher risk of falls and fractures in the pre-treatment period relative to the period directly after tr...

Characterising incident opioid use among incident users of prescription sedative hypnotics: A national cohort study.

To evaluate co-prescribing of sedatives hypnotics and opioids.... Retrospective study evaluating the association of patient characteristics and comorbidities with coprescribing.... Using the national Merative MarketScan Database between 2005 and 2018, we identified patients who received an incident sedative prescription with or without subsequent, incident opioid prescriptions w... Coprescription of sedative-hypnotics and opioids.... A total of 2 632 622 patients (mean (SD) age, 43.2 (12.34) years; 1 297 356 (62.5%) female) received incident prescriptions for sedatives over the course of the study period. The largest proportion of... Coprescription of sedatives with opioids was associated with the presence of comorbidities and substance use disorder, gender and types of sedatives prescribed at the index date. Additionally, more th...

Interactions of Insomnia and Sedative-Hypnotic Drug Use Associated with Frailty Over Time Among Older Adults.

Insomnia and frailty are prevalent in older adults. This study aimed to elucidate the impact of insomnia and sedative-hypnotic use on the frailty rate over time.... We used data from community-dwelling older adults (mean ± SD age = 69.4 ± 8.2 years) from the Healthy Aging Longitudinal Study in Taiwan (HALST). A total of 4,744 participants were included in the stu... The adjusted odds ratio (OR) of frailty was 1.41 (95% CI: [1.16, 1.72], Z-test statistics Z = 3.39, p <0.001) for insomnia and 1.52 ([1.16, 2.00], Z = 3.00, p = 0.0027) for sedative-hypnotic use. Inte... Insomnia and sedative-hypnotic use were independently associated with increased frailty. The implementation of nonpharmacological treatments to attenuate insomnia may reduce frailty rates....

Environmental scan of current strategies to decrease sedative-hypnotic drug use and promote sleep in hospital patients.

Sedative-hypnotic drugs are often initiated in hospital to manage insomnia and anxiety. Guidelines discourage their use, particularly in older adults, due to risks of falls, fractures, and delirium.... To identify publicly available resources to decrease the use of sedative-hypnotic drugs and promote sleep in hospital.... An advanced Google search with 6 search strategies was conducted. Key websites were also identified and searched. Hospital- or community-based resources using non-pharmacologic measures to reduce seda... A total of 79 resources met inclusion criteria, with 65 (82.3%) providing education and 31 (39.2%) describing sleep hygiene strategies. Other resources included deprescribing (17, 21.5%), relaxation t... Many resources were available to patients and healthcare providers to reduce inappropriate or ineffective use of sedative-hypnotic drugs and promote better sleep. Specific resources for the hospital s...

A Study on the Mechanism of the Sedative-hypnotic Effect of Cinnamomum camphora chvar. Borneol Essential Oil Based on Network Pharmacology.

In this paper, we investigated the sedative-hypnotic effect of Cinnamomum camphora chvar. Borneol essential oil (BEO, 16.4% borneol), a by-product of steam distillation of Cinnamomum camphora chvar. B...

Insights into patient characteristics and documentation of the use of sedative-hypnotic/anxiolytics in primary care: a retrospective chart review study.

Despite the known safety risks of long-term use of sedative-hypnotic/anxiolytic medications, there has been limited guidance for the safe and effective use of their chronic use in a primary care clini... Characterize patients who received a sedative-hypnotic/anxiolytic prescription in primary care, and (2) gain an understanding of the clinical documentation of sedative-hypnotic/anxiolytic indication a... A random selection of patients who received a prescription for a benzodiazepine or Z-drug hypnotic between January 2014 and August 2016 from four primary care clinics in Winnipeg were included. Data w... Records from a sample of 200 primary care patients prescribed sedative-hypnotic/anxiolytics were analyzed (mean age 55.8 years old, 61.5% ≥ 65 years old, 61.0% female). Long-term chronic use (≥ 1 year... A higher proportion of females and users 65 years and older received a prescription for a sedative-hypnotic/anxiolytic, consistent with previous studies on sedative-hypnotic use. We found inconsistenc...